Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have earned an average rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $33.00.

A number of analysts recently issued reports on the company. TD Cowen began coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set a “buy” rating on the stock. Weiss Ratings started coverage on Odyssey Therapeutics in a research report on Tuesday. They set a “sell (d+)” rating on the stock. JPMorgan Chase & Co. upped their target price on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 target price on shares of Odyssey Therapeutics in a research note on Thursday, June 18th. Finally, Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued an “overweight” rating for the company.

Odyssey Therapeutics Trading Up 0.0%

ODTX stock opened at $20.73 on Friday. The firm has a 50 day simple moving average of $18.30. The company has a market capitalization of $996.28 million and a price-to-earnings ratio of -3.06. Odyssey Therapeutics has a 12-month low of $15.10 and a 12-month high of $23.08.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. On average, equities research analysts anticipate that Odyssey Therapeutics will post -5.97 earnings per share for the current year.

About Odyssey Therapeutics

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.